ClinicalTrials.gg
Not yet recruitingNCT07414186DELTA-91Updated Feb 17, 2026

Study of Pre Hospital Management of Polytrauma Patients by Medical Teams From a Department in the Parisian Region

An observational study in Traumatic Injuries, Prehospital Emergency Care and Early Mortality, sponsored by Centre Hospitalier Sud Francilien. Not yet recruiting at 1 site in France. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Centre Hospitalier Sud Francilien · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
400
Ages
15 Years and older
Sex
All
01

Study summary

To study the impact of prehospital management duration by SMUR teams in the Essonne department (91) on early patient mortality (within 24 hours) and to analyze the procedures performed on scene.

The study hypothesis is that all-cause in-hospital mortality may be associated with the duration of prehospital care, with either a beneficial impact related to the performance of life-saving interventions or a negative impact due to prolonged time to access definitive treatment.

Identifying potential factors associated with prolonged prehospital management times could help define possible areas for improvement and future interventions.

Read the detailed description

Trauma is the leading cause of mortality among individuals aged 25-34 years, regardless of the mechanism of injury (road traffic accidents, falls from height, defenestration, ballistic or stab wounds, etc.).

More than 50% of trauma-related deaths occur within the first hour following injury, and over 80% occur within the first 24 hours.

Since the 1970s, the principle that definitive treatment should be initiated within one hour of the beginning of medical care for any life-threatening condition has been introduced. This concept, known as the "Golden Hour," has been applied in many fields, including trauma care, with the assumption that any delay is associated with decreased patient survival.

In the literature, prehospital time intervals do not consistently demonstrate a clear impact on mortality, with study results often being contradictory (1-11). A French study conducted within a SMUR-type system by Tobias Gauss in 2019 reported a significant linear increase in mortality associated with longer prehospital time (1).

In contrast, other American and European studies (3,7) did not find a significant association between prehospital care time and short- or long-term mortality, in healthcare systems that are not always comparable to the French SMUR model.

Overall, studies on this topic have yielded heterogeneous and sometimes conflicting results.

Nevertheless, these time intervals appear to play a more critical role in patients with penetrating trauma or with initial arterial hypotension.

The major challenge in the prehospital setting is therefore to rapidly identify patients for whom prolonged on-scene management would have a detrimental impact on survival.

The physician must then determine the optimal amount of time to spend at the scene during SMUR intervention, based on the risk-benefit balance for the patient.

Some patients will require longer prehospital management in order to perform life-saving procedures, whereas for others, for whom definitive treatment is exclusively hospital-based, any delay will be unacceptable.

02

Conditions studied

  • Traumatic Injuries
  • Prehospital Emergency Care
  • Early Mortality

Browse trials for

Keywords

  • prehospital emergency care
  • emergency medical services
  • wounds and injuries
  • trauma severity
  • time-to-treatment
  • on-scene time
  • early mortality
  • in-hospital mortality
  • advanced life support
  • emergency medical procedures
03

In context

Wounds and Injuries

2,217 studies on the registry are indexed under Wounds and Injuries; 441 are open to participants now.

This study's planned enrollment of 400 is above the median of 169 across 690 observational studies indexed under Wounds and Injuries.

Browse Wounds and Injuries studies →

Lead sponsor

Centre Hospitalier Sud Francilien is the lead sponsor of 58 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients managed prehospital by a SMUR team from the Essonne department (91) and transported to a Level 1 trauma center according to the predefined inclusion criteria

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 15 years (upper age limit for the pediatric population)
  • Severe trauma, defined as any road traffic accident, defenestration, fall from a height greater than 3 meters, stab wound, or ballistic injury requiring medically supervised transport to one of the Level 1 trauma centers in the Île-de-France region
  • Prehospital management provided by one of the SMUR teams in the Essonne department (91)

Exclusion criteria

Exclusion Criteria:

  • Patients declared dead at initial medical contact, without resuscitation initiated, or with resuscitation attempted and subsequently discontinued (non-return of spontaneous circulation)
  • Secondary inter-hospital transfer from another hospital to a Level 1 trauma center
  • Transport to a hospital for local computed tomography imaging only (without direct admission to a Level 1 trauma center)
  • Cases regulated (dispatched) by emergency coordination centers other than the Essonne (91) medical dispatch center
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
400 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients managed prehospital by a SMUR team from the Essonne department (91) and transported to a Le

    Patients managed prehospital by a SMUR team from the Essonne department (91) and transported to a Level 1 trauma center according to the predefined inclusion criteria.

06

What researchers measure

Primary outcomes

  1. Mortality

    All-cause in-hospital mortality within 24 hours

    Time frame: at day 0

Secondary outcomes

  1. Length of hospital stay and neurological outcome

    Total duration of hospital stay (in days) and neurological outcome at hospital discharge.

    Time frame: Up to one year

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07414186
Lead sponsor
Centre Hospitalier Sud Francilien
Responsible party
Sponsor
First posted
Feb 17, 2026
Start date
Mar 1, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Feb 17, 2026

Study contacts

Romain BARDELAY, MD
Contact
r.bardelay@gmail.com
01 61 69 31 50 ext. +33
Caroline TOURTE
Contact
caroline.tourte@chsf.fr
01 61 69 31 50 ext. +33
Romain BARDELAY, MD
principal investigator · Centre Hospitalier Sud Francilien

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion